🌐 ItalianoEnglishδΈ­ζ–‡
Full tender Source status Β· 2 documents Β· Completeness: 45%

TENDER ANALYSIS No. 2023-02_Perugia

Document generated on 04/06/26

TENDER IDENTIFICATION DATA

TENDER SUBJECTSupply of "Analytical Systems for the determination of the coagulation time (ACT)" - Preliminary market consultation preparatory to a negotiated procedure without prior publication of a contract noticeSource: AVVISO_-_ACT.doc: pagina 1
CONTRACTING AUTHORITYAzienda Ospedaliera di Perugia - Purchasing and Procurement DepartmentSource: AVVISO_-_ACT.doc: pagina 1
CIG (tender ID)Not stated
PROCEDURE TYPEPreliminary market consultation (art. 66 Legislative Decree 50/2016) preparatory to a negotiated procedure without prior publication of a contract notice pursuant to art. 63, paragraph 2, letter b), point 2) Legislative Decree 50/2016Source: AVVISO_-_ACT.doc: pagina 1
PLATFORMSubmission via certified email (PEC) to the address acquistiappalti.aosp.perugia@postacert.umbria.it (operators declare registration with MePA Consip, "Beni" initiative)Source: AVVISO_-_ACT.doc: pagina 1
PLACE OF PERFORMANCEAzienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, 06132 PerugiaSource: AVVISO_-_ACT.doc: pagina 1
AWARD CRITERIONNot stated
BID SUBMISSION DEADLINE7:00 PM on 6/02/2023 (deadline for responding to the preliminary market consultation)Source: AVVISO_-_ACT.doc: pagina 1
TOTAL AMOUNTEuro 36.000,00 excluding VAT per year (estimated base auction price for the annual requirement)Source: AVVISO_-_ACT.doc: pagina 1
PNRR (recovery funds)Not stated

PARTICIPATION REQUIREMENTS

ELIGIBILITY REQUIREMENTSRegistration with the Chamber of Commerce register (C.C.I.A.A.) for activities relating to the subject matter; registration with MePA Consip "Beni" initiative; entity referred to in art. 45 Legislative Decree 50/2016; possession of general requirements pursuant to art. 80 Legislative Decree 50/2016Source: ALL__A_-_istanza_di_partecipazione.doc: pagina 1
ECONOMIC CAPACITYNot stated
TECHNICAL CAPACITYSubmission of adequate technical documentation certifying the capacity to supply the requested systems, subject to assessment by expert personnelSource: AVVISO_-_ACT.doc: pagina 1
SOA CATEGORYNot stated
CREDIT LICENCENot stated
ADDITIONAL REQUIREMENTSNot stated
WHITE LISTNot stated

PRELIMINARY OBLIGATIONS

BID BONDNot stated
ANAC FEENot stated (participation in the consultation does not entail charges for operators)Source: AVVISO_-_ACT.doc: pagina 1
SITE INSPECTIONNot stated
SAMPLINGNot stated
TIMESTAMP / DIGITAL SIGNATURENot stated
TECHNICAL OFFERTechnical documentation required suitable to demonstrate compliance with the minimum technical requirements (not a binding offer - consultation phase)Source: AVVISO_-_ACT.doc: pagina 1
STAMP DUTYNot stated
LABOUR CONTRACT (CCNL)Not stated
ACCELERATION BONUSNot stated
SUBCONTRACTINGNot stated
RELIANCE (avvalimento)Not stated
RTI / CONSORTIUMIn the case of a temporary grouping to be established, the application must be signed by all members of the groupingSource: ALL__A_-_istanza_di_partecipazione.doc: pagina 1
CLARIFICATIONS DEADLINENot stated (administrative contacts: Dott. Glauco Fabbroni and Dott.ssa Beatrice Baldacci)Source: AVVISO_-_ACT.doc: pagina 1
FVOE (virtual file)Not stated

Custom questions

Is this an awardable tender or a preliminary phase?
It is a preliminary market consultation (art. 66 Legislative Decree 50/2016) preparatory to a future negotiated procedure without a notice: it is not yet an awardable tender, but serves to confirm the non-substitutability or to identify additional operators able to supply the ACT system. Source: AVVISO_-_ACT.doc: pagina 1
Is there a risk of a single supplier/exclusivity?
Yes: the Authority declares that, based on the information in its possession, there would be a single economic operator able to provide the supply, the case under art. 63 par. 2 letter b) p.2). The minimum technical requirements are detailed (microdroplet system, ACT for high heparin dosages in half the time up to 350 sec). Source: AVVISO_-_ACT.doc: pagina 1
Who is the RUP (Procurement Officer) and how does one respond?
RUP: Dott. Glauco Fabbroni. The response must be sent via PEC by 7:00 PM on 6/02/2023 with a specific wording in the subject line. Source: AVVISO_-_ACT.doc: pagina 1

TECHNICAL ANALYSIS

Subject: Supply of Analytical Systems for the determination of the coagulation time (ACT) - preliminary market consultation preparatory to a negotiated procedureTotal base amount: € 36.000,00 excluding VAT (annual, estimated base auction price)No. of lots: 1

LOT 1 β€” Analytical Systems for the determination of the coagulation time (ACT)

CIGNot stated
Description / what it isSupply of POCT systems for measuring the activated coagulation time (ACT), typically used for monitoring high-dose heparin therapy (e.g. hemodynamics lab, cardiac surgery, dialysis). The ACT instrument and the consumables (cartridges/reagents) to run the tests are required. For technical/sales staff: it is a microdroplet coagulation POCT, a niche segment with a market controlled by few suppliers.
System / instrumentationPortable microdroplet ACT instrument, with direct measurement of the fibrin clot, rechargeable lithium batteries, on-board barcode reader, dedicated port for data transmission, option for external printer
Base amount€ 36.000,00 excluding VAT per year
Volumes4 Systems (instruments) and material for 4,500 tests per year (estimated annual requirement)
DurationNot stated (requirement expressed on an annual basis)
Required tests
  • Activated coagulation time (ACT)
  • ACT for high heparin dosages (executed in half the time, up to 350 sec)
  • Blood quality control
  • Electronic quality control
Technical requirements
  • Microdroplet system
  • Blood and electronic quality control tests
  • Reduced interference from drugs or magnetic fields
  • Storage of the patient test and the quality control
  • Small instrument size and rechargeable lithium batteries
  • Direct measurement of the fibrin clot
  • On-board barcode reader
  • Programming of automatic execution of internal electronic quality controls
  • Traceability of operator, patient, quality control
  • Data transmission with dedicated port
  • Stability of reagents/cartridges at least 2 months at room temperature (sealed package)
  • Stability of reagents/cartridges at least 24 hours once package is opened
  • Option for external printer
  • Execution of ACT test for high heparin dosages in half the time, up to 350 sec
SamplingNot stated (technical documentation required to substantiate the requirements)
NotesSHOWSTOPPER: the Authority explicitly declares that there would be a SINGLE economic operator able to supply the system (premise of art. 63 par. 2 letter b p.2 - non-substitutability). The technical requirements are very specific (microdroplet, direct measurement of the fibrin clot, ACT high dosages in half the time up to 350 sec) and appear designed around a single technology/brand. Firsteck competitiveness very low unless an equivalent microdroplet ACT system is available in the portfolio. Furthermore, the phase is a market consultation closed on 6/02/2023, widely expired.
Sources
  • AVVISO_-_ACT.doc: pagina 1

Assessment for Firsteck Bio

The product falls within the Firsteck focus as coagulation POCT (microdroplet ACT system, rapid point-of-care test). However, feasibility is practically nil: it is a preliminary market consultation expired more than three years ago (deadline 6/02/2023) and the Authority declares the existence of a single operator able to supply, with very stringent and effectively unique technical requirements. It makes sense only as market/historical information; it is not biddable.